Igarashi Yuichi, Wada Haruka, Muto Masato, Sone Ryohei, Hasegawa Yoshinori, Seino Ken-Ichiro
Division of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
MEDINET Medical Institute, MEDINET Co., Ltd., Tokyo, Japan.
Inflamm Regen. 2025 Jan 24;45(1):2. doi: 10.1186/s41232-025-00364-7.
For the treatment of liver fibrosis, several novel cell therapies have been proposed. Autologous macrophage therapy has been reported as one of the promising treatments. So far, most studies have used colony-stimulating factor 1 (CSF-1) to induce the differentiation of macrophage progenitor cells. The receptor for CSF-1, CSF-1R possesses another ligand, interleukin 34. However, the therapeutic capacity for liver fibrosis by interleukin 34-induced macrophages has not been evaluated.
We have employed acute (bile duct ligation) and chronic (administration of carbon tetrachloride or thioacetamide) liver fibrosis models. Using these models, we evaluated the therapeutic capacity of macrophages induced by interleukin 34-based conditions. In most experiments, interleukin 4 was also added to the differentiation process to induce alternative-activated macrophages. As a mechanism analysis, we have examined liver inflammation and damage, the status of stellate cells, and the immunosuppressive capacity of the macrophages. Human macrophages were differentiated from CD14 monocytes and analyzed.
In both acute and chronic liver damage experiments, interleukin 34-induced macrophages significantly ameliorated liver fibrosis. The addition of interleukin 4 to the differentiation process resulted in an increase of obtained macrophages and a bias to alternative activated macrophages (so-called M2). The alternative activated macrophages (M2-type) showed a reproducible therapeutic effect of liver fibrosis with a suppression of parameters of liver inflammation and damage, stellate cells, and T cell activation. Similar macrophages could be differentiated from human CD14 monocytes in the presence of interleukin 34 plus interleukin 4, and a therapeutic effect was observed using a humanized mouse model.
Interleukin 34-induced macrophages, particularly when additionally stimulated with interleukin 4, significantly ameliorated the liver fibrosis.
对于肝纤维化的治疗,已经提出了几种新型细胞疗法。自体巨噬细胞疗法已被报道为有前景的治疗方法之一。到目前为止,大多数研究使用集落刺激因子1(CSF-1)来诱导巨噬细胞祖细胞的分化。CSF-1的受体CSF-1R拥有另一种配体,即白细胞介素34。然而,白细胞介素34诱导的巨噬细胞对肝纤维化的治疗能力尚未得到评估。
我们采用了急性(胆管结扎)和慢性(给予四氯化碳或硫代乙酰胺)肝纤维化模型。利用这些模型,我们评估了基于白细胞介素34条件诱导的巨噬细胞的治疗能力。在大多数实验中,白细胞介素4也被添加到分化过程中以诱导替代性活化巨噬细胞。作为机制分析,我们检查了肝脏炎症和损伤、星状细胞的状态以及巨噬细胞的免疫抑制能力。人巨噬细胞从CD14单核细胞分化而来并进行分析。
在急性和慢性肝损伤实验中,白细胞介素34诱导的巨噬细胞均显著改善了肝纤维化。在分化过程中添加白细胞介素4导致获得的巨噬细胞增加,并偏向于替代性活化巨噬细胞(所谓的M2型)。替代性活化巨噬细胞(M2型)对肝纤维化具有可重复的治疗效果,可抑制肝脏炎症和损伤、星状细胞以及T细胞活化的参数。在白细胞介素34加白细胞介素4存在的情况下,类似的巨噬细胞可从人CD14单核细胞分化而来,并在人源化小鼠模型中观察到治疗效果。
白细胞介素34诱导的巨噬细胞,特别是在额外用白细胞介素4刺激时,可显著改善肝纤维化。